LEARNING OBJECTIVES

• Summarize the findings from key clinical trials presented at the 2023 ASH meeting that will impact standards of care in hematology
• Discuss the latest findings in genetic profiling, cytogenetics, and molecular biology, and describe how this information can be utilized in determining patient prognosis and treatment course
• List novel, targeted therapies in development for hematology and explain the therapeutic rationale for these agents
• Describe the latest advances in the field of Classical Hematology that will impact patient treatment
• Outline how clinical trial data can be efficiently incorporated into community-based hematology practice

ACCREDITATION

• Temple Health designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the educational activity.

For more information please visit the official event page.